Get the Stockscreener App
43.66
12.12%
4.72
After Hours:
43.66
Sionna Therapeutics Inc stock is traded at $43.66, with a volume of 270.15K.
It is up +12.12% in the last 24 hours and up +2.73% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$38.94
Open:
$38.68
24h Volume:
270.15K
Relative Volume:
0.95
Market Cap:
$1.95B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+18.00%
1M Performance:
+2.73%
6M Performance:
+223.41%
1Y Performance:
+0.00%
1-Day Range:
$38.68
$43.93
1-Week Range:
$36.81
$43.93
52-Week Range:
$7.255
$43.93
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
43.66 | 1.74B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
Is Sionna Therapeutics Inc. stock a smart buy before Fed meetingGap Down & High Yield Equity Trading Tips - newser.com
Will Sionna Therapeutics Inc. stock reach Wall Street targetsMarket Risk Report & Reliable Intraday Trade Alerts - newser.com
Ra Capital sold Sionna Therapeutics (SION) shares worth $5.5m By Investing.com - Investing.com Canada
Ra Capital sold Sionna Therapeutics (SION) shares worth $5.5m - Investing.com
[Form 4] Sionna Therapeutics, Inc. Insider Trading Activity - Stock Titan
Owner RA Capital Management LP Sells 136,351 ($5.5M) Of Sionna Therapeutics Inc [SION] - TradingView
Is Sionna Therapeutics Inc. stock a safe buy before earningsTrade Risk Report & Risk Controlled Daily Plans - newser.com
Owner RA Capital Healthcare Fund LP Files To Sell 2,278 Of Sionna Therapeutics Inc [SION] - TradingView
How Sionna Therapeutics Inc. stock performs in rising dollar environmentMarket Growth Summary & Short-Term Trading Opportunity Alerts - newser.com
What Fibonacci levels say about Sionna Therapeutics Inc. reboundJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - newser.com
What Wall Street predicts for Sionna Therapeutics Inc. stock price2025 Geopolitical Influence & Capital Protection Trading Alerts - newser.com
Will Sionna Therapeutics Inc. stock go up soonJuly 2025 Trade Ideas & Safe Entry Point Alerts - newser.com
BTIG Research Initiates Coverage on Sionna Therapeutics With Buy Rating, $50 Price Target - MarketScreener
BTIG Initiates Coverage of Sionna Therapeutics (SION) with Buy Recommendation - Nasdaq
How analysts rate Sionna Therapeutics Inc. stock todayQuarterly Investment Review & Free Expert Approved Momentum Trade Ideas - newser.com
BTIG Assigns Buy Rating to Sionna Therapeutics, Citing Innovative Cystic Fibrosis Therapies and Strong Market Potential - TipRanks
Is Sionna Therapeutics Inc. stock a safe haven assetJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy - MSN
Relative strength of Sionna Therapeutics Inc. in sector analysisQuarterly Earnings Report & Real-Time Volume Analysis - newser.com
Sionna Therapeutics Inc. stock trendline breakdownJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
Will Sionna Therapeutics Inc. rebound enough to break evenWeekly Profit Summary & Stepwise Trade Execution Plans - newser.com
Why Sionna Therapeutics Inc. stock attracts global investorsBear Alert & Safe Entry Point Identification - newser.com
Is Moongipa Capital Finance Limited a Top Alpha Generator for Growth PortfoliosStock Screening Results & Hidden Gems with Outstanding Profit Margins - earlytimes.in
Is Sionna Therapeutics Inc a good long term investmentSell Signals and Alerts & Double Digit Capital Growth - earlytimes.in
Sionna Therapeutics Inc Stock (SION) Financials Data
There is no financial data for Sionna Therapeutics Inc (SION). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):